In Crohn's disease (CD), hierarchical architecture of the inflammatory network, including subordination of IL-18, an IFN-γ-inducing cytokine, to the inflammasome, have remained undeciphered. Heterogeneity among patients of such a subordination cannot be evaluated by animal models, monofactorial in their etiology and homogenous in disease progression. To address these issues, we set up an ex vivo model of inflamed mucosa explant cultures from patients with active long-standing CD. Th1 cytokine production, especially IFN-γ and IL-18, was assessed in relation with inflammation intensity. Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD. We showed a correlation between secreted IFN-γ/ IL-18 levels, and caspase-1 activation, with inflammation intensity of intestinal CD mucosa explants. Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-γ response, and a heterogenous responder group, in which both IL-18 and IFN-γ responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD. These findings bring out the concept of heterogeneity of subordination of the Th1 response to inflammasome activation among CD patients. This ex vivo model should have therapeutic relevance in allowing to determine eligibility of CD patients for new targeted therapies.
In Crohn's disease (CD), hierarchical architecture of the inflammatory network, including subordination of IL-18, an IFN-γ-inducing cytokine, to the inflammasome, have remained undeciphered. Heterogeneity among patients of such a subordination cannot be evaluated by animal models, monofactorial in their etiology and homogenous in disease progression. To address these issues, we set up an ex vivo model of inflamed mucosa explant cultures from patients with active long-standing CD. Th1 cytokine production, especially IFN-γ and IL-18, was assessed in relation with inflammation intensity. Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD. We showed a correlation between secreted IFN-γ/ IL-18 levels, and caspase-1 activation, with inflammation intensity of intestinal CD mucosa explants. Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-γ response, and a heterogenous responder group, in which both IL-18 and IFN-γ responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD. These findings bring out the concept of heterogeneity of subordination of the Th1 response to inflammasome activation among CD patients. This ex vivo model should have therapeutic relevance in allowing to determine eligibility of CD patients for new targeted therapies. Initiator events thought to be involved in the pathogenesis of Crohn's disease (CD), a complex inflammatory bowel disease (IBD), 1 all converge to a dysregulation of the intestinal mucosa immune homeostasis. They include a downregulation of IL-10 and/or transforming growth factor-β (TGF-β) signaling-cytokines which have pivotal immunoregulatory functions in the human intestinal mucosa-2-4 which has been reported in subgroups of CD patients. [5] [6] [7] [8] It is likely that these initiator events are no more drivers in a sustained, chronic intestinal inflammation like CD. Indeed, the clinical studies published indicate no relevant advantage of IL-10 therapy in CD. [9] [10] [11] So, the subordination to initiator events seems to progressively change over time in the perpetuation of the inflammation in CD, and thus biological therapies of long-standing CD cannot be predicted on the basis of the delineation of initiator events. In fact, when considering the biological therapies of long-standing CD, the issue at stake is how to decipher the driving signaling pathways. Interestingly, anti-tumor necrosis factor-α (TNF-α) therapy, which has significant benefit for CD patients in terms of clinical remission [12] [13] [14] is an extension of clinical studies in rheumatoid arthritis and has not been identified by tracking a scientific concept. 15 Numerous murine models of chronic intestinal inflammation close to human IBD have been established in order to study IBD pathogenesis, and much hope has been placed in predicting in these models the efficacy of new drugs in human IBD. However, very few of these murine models has proven useful to select a relevant biological therapy amenable to the clinical practice. For example, anti-TNF-α treatment can ameliorate or aggravate inflammation, depending on the mouse model used. 16 Therefore, it is important to setup a preclinical model able to decipher the driving signaling pathways that maintain a sustained inflammation in CD. Our reasoning was that ex vivo explant cultures of inflamed mucosa from full blown CD patients can be relevant to the in vivo situation, and that their pharmacological manipulation can help decipher the subordination of the elements of the complex cytokine network to key molecular platforms, that can be potential targets for biotherapies. In this work, we make the hypothesis of a maintenance of the maturation pathway of proinflammatory cytokines in tissues of patients with active long-standing CD, despite the modifications resulting from disease progression and treatments. As a proof of concept, we chose to examine the maintenance of the inflammasome pathway (caspase-1-IL-18-IFN-γ axis) in full blown CD. The inflammasome is a multiprotein complex that includes the effector protein caspase-1, which is the main processing enzyme for maturation of IL-1β and IL-18. 17 IL-18 can in turn induce the production and release of IFN-γ, the prototypical Th1 cytokine. 18 The human normal intestinal mucosa is a reservoir of procaspase-1 and pro-IL-18, present in epithelial cells and in some lamina propria macrophages, 19, 20 that can be rapidly activated under various stress conditions and can initiate a Th1 response. 4 However, in a sustained chronic inflammation such as CD, the status of caspase-1 and the subordination of the Th1 response to caspase-1 activation are so far unknown.
In this work, we examined in the ex vivo explant culture model of inflamed mucosa from CD patients: (i) the status of the caspase-1/IL-18/IFN-γ axis in relation with the intensity of histological lesions, and (ii) the subordination of the IL-18 and IFN-γ responses to caspase-1, using pharmacological inhibition and a multiparametric approach. We show here that the activation of caspase-1, as well as the IL-18 and IFN-γ responses are related to the intensity of the inflammatory lesions in active long-standing CD. Interestingly, we also show a heterogeneity in the subordination of the IL-18/IFN-γ response to caspase-1 activation in CD patients.
MATERIALS AND METHODS Patients
Crohn's disease patients Intestinal samples (ileum from macroscopically inflamed areas and matched adjacent colon when possible) were obtained from 28 patients undergoing ileocolectomy or colectomy for CD between 2011 and 2013 (University Hospital of Nantes). The main clinical features of the CD patients and their treatment before surgery are mentioned in Table 1 .
Normal controls
Intestinal samples were also collected from macroscopically and microscopically unaffected colon of eight patients undergoing surgery for colorectal cancer, taken at least at 10 cm downstream the tumor.
All tissue fragments were processed according to the French guidelines for research on human tissues. Informed patient consent was obtained according to the French bioethics law.
Explant Cultures
The human normal colonic mucosa from 'normal controls' (n = 8) was carefully stripped from the underlying compartment as previously described. 3, 4 Regarding inflamed tissue from CD patients (n = 28), the muscle layers and most of the submucosa were removed. Fragments of about 40 mg each were cut, pinned in Sylgard-coated Petri dishes, and maintained for 24 h in culture in RPMI/bovine serum albumin (BSA)/antibiotics/fungizone, as previously described. 3 The explants were maintained at 37°C in a 95% oxygen, 5% carbon dioxide humid atmosphere on a rocking platform at low speed for 24 h. At the end of the 24 h culture, the supernatants were centrifuged and aliquots were stored at − 80°C for further analysis. Each cultured explant was cut into two fragments: one was used for morphological/ immunohistochemical analyses after formalin fixation and paraffin embedding (see below), the other was stored at − 80°C for further analysis (eg caspase-1 activity). Inflamed mucosa from 21 CD patients was cultured in the absence or in the presence of the caspase-1 inhibitor YVAD-FMK (2 μM; Biovision, Clinisciences, Montrouge, France). For each patient, at least four mucosa explants were put in culture for each experimental condition. After the 24-h incubation, culture medium was collected, centrifuged and stored at − 80°C until use. Tissue fragments were stored at − 80°C, and processed in several cases for determination of caspase-1 activity. Before culture, four microdissected explants were fixed in formalin, embedded in paraffin, and subjected to histological analysis (Hematoxylin-eosin (HE) standard staining) to assess inflammation as follows: no inflammation; weak inflammation (a few neutrophils and mild inflammatory infiltrate as well as mild abnormal villus/crypt architectural abnormalities); or strong inflammation (ulcerations, strong inflammatory infiltrate with many neutrophils, loss of mucosal architecture). HE staining was also used to assess the overall morphology before culture (T0) and after a 24-h culture. In addition, immnohistochemistry using a M30 antibody (Roche Diagnostics, 1:100), specific for apoptotic epithelial cells, 21, 22 and an antibody directed to active caspase-3 (Cell Signaling, 1:800), which labels all apoptotic mucosa cells (epithelial and immune cells) was performed both at T0 and after the 24-h culture. As shown in Supplementary Figure S1 , the 24-h culture does not alter the overall architecture, as well as the pattern of epithelial or immune cells apoptosis, compared with T0.
Cytokine Determination Assay
The following cytokines were determined by enzyme-linked immunosorbent assay (ELISA) in samples of culture medium collected at time point 24 h, according to the manufacturers' protocols: IL-18 (Bender MedSystems; eBiosciences, Paris, France), IFN-γ (Eurobio, Courtaboeuf, France), IL-17 A (PeproTech, Neuilly, France). Results are expressed as pg/ml.
Caspase-1 Activity Assay
Inflamed mucosa explants from CD patients before culture were lyzed for 1 h on ice, centrifuged at 12 000 g for 20 min. Caspase-1 activity was assessed in the lysates using the Caspase-1 Colorimetric Assay Kit (Biovision, Clinisciences, Immunohistochemistry Cells containing active caspase-1 were detected by immunohistochemistry on paraffin sections of CD mucosa, after antigen retrieval (citrate buffer pH 6). Sections were then stained with antibodies directed to active caspase-1 p20 antibodies (1:100; Cell Signaling, Danvers, MA, USA), or T-bet (clone 4B10, Santa Cruz, 1:200) or granzyme B (GrzB) (Novocastra, 1:50). The immunological reaction was visualized using an Envision kit (Dako, Les Ulis, France). Diaminobenzidine was used as a chromogen. Sections were counterstained with haematoxylin. The number of T-bet-and GrzB-positive cells per field was assessed by counting at least 15 consecutive fields at a × 400 magnification.
Statistics
The Mann-Whitney test was used to assess differences in cytokine levels, using GraphPad Prism (GraphPad Software Inc, La Jolla, CA). Correlation between IL-18 and IFN-γ levels, analyzed using Spearman's rank correlation, as well as association between IL-18 low/high and IFN-γ low/high subgroups, tested by the Chi-square test, were performed using the SAS 9.3 software. P-values o0·05 were considered significant.
RESULTS

Validation of Intramucosal Caspase-1 Activation and IL-18 Production as Markers Related to the Inflammation Intensity in CD Explant Cultures
The ex vivo model of explant cultures was used to examine the spontaneous release of mature IL-18 by the inflamed mucosa of CD patients, compared with the human normal colonic mucosa of control patients. In CD, the intensity of inflammation in the small intestine or colon was determined on mucosa before culture, and evaluated as no inflammation, weak or strong inflammation, as mentioned in the Materials and Methods section. As shown in Figure 1a , the amounts of mature IL-18, assessed by ELISA in the supernatants of 24-h explant cultures were very low in the normal colonic mucosa from 'control' patients. By contrast, high to very high levels of IL-18 were released by the strongly inflamed mucosa explants of CD patients (with interindividual variations). Weakly inflamed mucosa explants secreted significantly lower levels of IL-18 compared with strongly inflamed mucosa (Figure 1a) . In seven patients undergoing an ileocolectomy, paired explants of ileum and colon could be put in culture for 24 h. In all these cases, the inflammation was weak or absent in the colon and strong in the small intestine. In most cases, IL-18 levels were higher in the inflamed mucosa (ileum) than in the weakly inflamed or noninflamed mucosa (colon; Figure 1b Heterogeneity of cytokine subordination in Crohn's disease A Jarry et al inflammation intensity, they were not related to the clinical features of CD patients.
We next assessed the status of caspase-1, known to mediate IL-18 processing, in the inflamed mucosa of CD patients, by two complementary methods: a caspase-1 activity assay, based on cleavage of a selected substrate detected by spectrophotometry, and in situ detection of active caspase-1 by immunohistochemistry. As shown in Figure 2 (upper panel), caspase-1 activity, determined on cell lysates of mucosa from CD patients before culture, was significantly higher in cases with severe mucosal inflammation compared with those with weak or no inflammation. In situ detection of active caspase-1 using anti-caspase-1 p20 antibodies showed a strong immunostaining in a few epithelial cells in weakly and strongly inflamed CD mucosa, as well as in immune cells of the inflammatory infiltrate, more numerous in cases with strong mucosal inflammation compared with those with weak inflammation (Figure 2, lower panel) .
Relation Between IL-18 and IFN-γ Responses in the Inflamed Mucosa of CD Patients
We next addressed the issue of the possible correlation between IL-18, known as an IFN-γ-inducing cytokine, and the IFN-γ response in the inflamed mucosa explant cultures from CD patients. First, IFN-γ levels released in the supernatants of 24-h explant cultures were significantly higher in the strongly inflamed mucosa than in the weakly inflamed mucosa from CD patients (mean 209±34 pg/ml vs 43±16 pg/ml), whereas the human normal colonic mucosa explant cultures did not produce IFN-γ (2.6±0.7 pg/ml; Figure 3a) . IFN-γ levels, Caspase-1 activation in relation with the inflammation intensity in the mucosa of CD patients. The histogram shows caspase-1 activity, detected in lysates of mucosa from CD patients before culture, using a colorimetric assay with a specific substrate (YVAD-pNA). Absorbance at 405 nm. Mean±s.e.m. of four CD mucosae with weak inflammation (two ileum, two colon) and four CD mucosae (ileum) with strong inflammation. Statistical analysis was performed with the Mann-Whitney nonparametric test. Images show immunostaining of active caspase-1 in a weakly inflamed and in a strongly inflamed ileal mucosa from CD patients, using an antibody directed to caspase-1 p20. In the weakly inflamed mucosa (left), active caspase-1 (brown) is present in the epithelial cells of some crypts (arrows) and in some mononuclear cells of the mucosa inflammatory infiltrate (arrowheads). In the strongly inflamed mucosa (right), numerous mononuclear cells of the dense inflammatory infiltrate express active caspase-1. Nuclei are counterstained in blue with haematoxylin. The scale bar represents 100 μm. CD, Crohn's disease.
linked in CD patients with the inflammation intensity, were not related to the clinical features of patients. Noteworthy, the number of cells immunostained with T-bet, a Th1-specific transcription factor that controls the expression of IFNγ, 23 was significantly higher in the strongly inflamed mucosa than in the weakly inflamed mucosa (Figure 3b) . Then, the correlation between IL-18 and IFN-γ levels was evaluated using the Spearman rank correlation coefficient test, taking into account first all the explant cultures from CD patients whatever the intensity of inflammation (weak or strong). No significant correlation was found between IL-18 and IFN-γ levels (although there was a tendency (P = 0.068); Figure 3c ). Then, a cut-off value selected on the basis of median values of both IL-18 and IFN-γ secreted by strongly inflamed mucosa explants (dotted lines in Figure 3b ), allowed us to determine subgroups (IL-18 low or high and IFN-γ low or high). As shown in Figure 3d , there were concurrent high IL-18 and IFN-γ levels or low IL-18 and IFN-γ levels in 23/34 explant cultures from 28 CD patients ie, in 68% cases, and no relation in 32% cases (11/34) . In this context, the determination of the levels of two cytokines released by inflamed mucosa explant cultures is insufficient to infer a hierarchical subordination between these cytokines.
Subordination of the IL-18 and IFN-γ Responses to Caspase-1 Activation in the Inflamed Mucosa of CD Patients
In order to determine whether the IL-18 and IFN-γ responses were dependent on caspase-1 activation, inflamed mucosa explant cultures from CD patients (n = 21 cases) were incubated or not in the presence of the specific caspase-1 inhibitor YVAD-FMK (2 μM) for 24 h. The cytokine response was considered to be caspase-1-dependent when the level of the cytokine was significantly lower in the presence of YVAD compared with control cultures without YVAD (at least four inflamed mucosa explants per condition in a given patient). As shown in Figure 4a , the IL-18 response was dependent on caspase-1 activation in 43% cases, and the IFN-γ response was dependent of caspase-1 in 33% cases (the percent inhibition of the IL-18 and IFN-γ responses by YVAD ranged from 40 to 70%). In addition, in a given patient, when the IL-18 response was caspase-1-dependent, the IFN-γ response was also caspase-1-dependent in 70% cases; in the other 30% cases, the IFN-γ response (caspase-1-independent) was very low. When the IL-18 response was independent of caspase-1, the IFN-γ response was also in all cases caspase-1-independent. In some of the cases in which the IL-18/IFN-γ response was independent of YVAD, the efficacy of YVAD was verified by assessing caspase-1 activity, which was lower in YVAD-treated explant cultures compared with control explant cultures. Figure 4b and c show cases with YVADdependent and YVAD-independent cytokine responses, respectively. We next examined the possible involvement of an alternate pathway, which could be responsible for the caspase-1-independent IL-18 response in Crohn's disease patients. A potential candidate could be granzyme B (GrzB), a serine protease known to cleave IL-18 in in vitro assays, 24 and to process IL-18 independently of caspase-1 in keratinocytes. 25 Interestingly, the number of GrzB-positive cells was significantly higher in strongly inflamed CD mucosa compared with weakly inflamed CD mucosa (Figure 5a ). We next examined the possible correlation between the number of GrzB-positive cells and the subordination of the IL-18 response to caspase-1. As shown in Figure 5b , the number of GrzB-positive cells was significantly higher in the group of patients with a YVADindependent IL-18 response than in the group of patients with a YVAD-dependent IL-18 response.
IL-17 Response in the Inflamed Mucosa of CD Patients
As IL-17 is a known component of the immune response in CD, 4, 26 we examined the levels of IL-17A released in the supernatants of the 24-h cultures. As shown in Figure 6a , IL-17A levels, very low in normal colonic mucosa and in weakly inflamed mucosa from CD patients, were moderate to high in strongly inflamed mucosa from CD patients (mean: 152±31 pg/ml). In seven patients undergoing an ileocolectomy, paired fragments of both ileum (strong inflammation) and colon (weak or no inflammation) could be put in culture for 24 h. In cases in which IL-17 levels were high in the inflamed ileum, IL-17 levels were significantly lower in the weakly inflamed colon (Figure 6b ). Noticeably, YVAD was unable to modify the IL-17 response, which served as a 'negative control' in our experiments (Figure 6c ). Altogether, our study established IL-17 as an inflammatory cytokine independent from the caspase-1-IL-18-IFN-γ axis.
DISCUSSION
Several studies, based on cultures of endoscopic biopsies or on isolated lamina propria mononuclear cells from CD patients, described increased levels of various proinflammatory cytokines levels produced in active, long-standing CD, including TNF-α, IFN-γ, IL-18, IL-17, IL-12, and IL-23. [26] [27] [28] [29] However, it remains unknown how these cytokines are integrated in the network driving the evolution of the disease. Recently, a new cytokine taxonomy of human chronic inflammatory diseases has been proposed, based on clinical trials aimed at defining the potential driver cytokines. 30 However, in this hierarchical taxonomy, little is known about the cytokine framework of CD, whose main driving cytokine rests on TNF-α. In this context, we propose a new preclinical approach aimed at evaluating (i) the subordination hierarchy of the cytokine network operating in active, long-standing CD, and (ii) the potential heterogeneity of this subordination.
In this work, we first evaluated the hirerarchical subordination of the IL-18-Th1 axis to caspase-1 activation in full blown CD, using ex vivo explant cultures of inflamed mucosa subjected or not to pharmacological inhibition of caspase-1. Our rationale for focusing on the caspase-1/IL-18 axis arose out of our previous studies showing that in the human normal intestinal mucosa, activation of the epithelial and macrophage inflammasome is the key to the initiation of Figure 5 Granzyme B (GrzB) expression in CD mucosa, in relation with the inflammation intensity and the subordination of the IL-18 response to caspase-1. The number of GrzB-positive cells was evaluated on explants of normal mucosa, and of weakly or strongly inflamed mucosa of CD patients (a), as well as on CD mucosa with a YVAD-dependent or YVAD-independent IL-18 response. Images show representative cases of GrzB immunostaining in the ileal mucosa of a patient with a YVAD-dependent IL-18 response (few GrzB-positive cells in brown, arrows) and in a patient with a YVAD-independent IL-18 response (more numerous GrzB-positive cells in brown). In a and b, light gray circles indicate explant cultures from the colon and black circles from the ileum. The scale bar on the images represents 50 μm. CD, Crohn's disease. a Th1 inflammatory response. 4 Up to now, the role of caspase-1 in a sustained intestinal inflammation has been studied mainly in mouse models with a genetic deficiency in a component of the inflammasome pathway including caspase-1, in association with a chemical inflammatory stress (DSS or TNBS). 31 However, these experimental conditions are far from the human inflammatory bowel diseases. In fact, these animal models provide clues only on the caspase-1-dependent susceptibility of the mouse model to a chemically induced stress. These models do not provide information on the role of caspase-1 in CD. Interestingly, a very recent report emphasizes the important role of the inflammasomecaspase-1 pathway in driving the progression of inflammation in the IL10-deficient mouse model of enterocolitis. 32 In fact, in this model, caspase-1 inhibition had a strong beneficial effect. However, the IBD mimicry of this model is very limited. First, it results from a monogenic alteration, whereas human IBD is thought to have a multifactorial origin. In addition, the choice of a unique inbred line of mice guarantees homogeneous responses to the manipulation of caspase-1. These are severe limitations that can only miss the crucial issue of the heterogeneity of the subordination of the downstream targets of caspase-1 to caspase-1 inhibition.
In this context, the best model for studying the cytokine pathway in CD is obtained by translating the lesion itself ex vivo. The first step using this approach was to show a correlation between the levels of IFN-γ, IL-18, caspase-1 activation, and the intensity of the inflammatory lesions in CD. This finding suggests that the caspase-1-IL-18-IFN-γ axis is conserved in active, long-standing CD, and could have a role in the maintenance of a sustained inflammation, whatever the clinical phenotype of CD patients. However, comparison of the levels of two cytokines (IL-18 and IFN-γ) does not inform about their hierarchical order and their potential subordination to caspase-1 activation. This issue can be addressed using a pharmacological approach, ie, an inhibition of caspase-1 activation by the caspase-1 inhibitor YVAD. This approach allowed us to demonstrate an heterogeneity of the subordination of the IL-18-IFN-γ response to caspase-1 activation in CD patients. Indeed, we define herein a population of patients with a caspase-1-dependent IL-18-IFN-γ response, and another population of patients with a caspase-1-independent IL-18-IFN-γ response. This latter population suggests the existence of alternate pathways of activation of the IL-18-IFN-γ axis. There are several candidate proteins such as proteinase-3 and the serine protease GrzB. 33 Evidence from the potential involvement of these candidate proteins is often indirect. To our knowledge, only GrzB was found to be involved in the maturational cleavage of IL-18 in in vitro assays. 24, 25 Interestingly, we found an increased number of GrzB-positive cells in the inflamed mucosa of CD patients, in relation with the inflammation intensity. In addition, GrzB-positive cells were significantly higher in patients with a YVAD-independent IL-18 response than in patients with a YVAD-dependent IL-18 response.
In conclusion, here we show for the first time that the human ex vivo model of intestinal inflamed mucosa explant cultures from CD patients is a powerful tool, not only to qualitatively and quantitatively evaluate inflammatory cytokines, but also to determine the hierarchical subordination of cytokines to a given signaling pathway. This approach is crucial for developing a hierarchical taxonomy of cytokines in CD. In addition, our study brings out the concept of the heterogeneity of the subordination of the Th1 response to inflammasome activation among patients. This concept of heterogeneity is the basis for developing targeted therapies, well known in oncology. In fact, in this field, the heterogeneity of the response to a targeted therapy requires a screening of candidate patients with available biomarkers predictive of the response. Here we show that this concept applies to CD. In fact, predicting the efficacy of a candidate biotherapy depends on the availability of a preclinical screening test. Thus, the use of mucosa explant cultures for treatment testing might be useful in this context of personalized medicine.
